Table 1.
Baseline characteristics of treated cohort, by treatment group
| Total (N=352) | Telaprevir (n=211) | Boceprevir (n=141) | |
|---|---|---|---|
| Age, median (range) | 56 (21, 70) | 57 (25, 70) | 56 (21, 69) |
| Male | 213 (61%) | 125 (59%) | 88 (62%) |
| Race/ethnicity | |||
| Black | 52 (15%) | 34 (16%) | 18 (13%) |
| Asian | 18 (5%) | 8 (4%) | 10 (7%) |
| Hispanic | 52 (15%) | 31 (15%) | 21 (15%) |
| White non-Hispanic | 223 (63%) | 135 (64%) | 88 (62%) |
| Unknown/other | 7 (2%) | 3 (1%) | 4 (3%) |
| Health plan membership | |||
| <12 months | 14 (4%) | 8 (4%) | 6 (4%) |
| 12–59 months | 122 (35%) | 74 (35%) | 48 (34%) |
| ≥60 months | 216 (61%) | 129 (61%) | 87 (62%) |
| Diabetes | 58 (16%) | 34 (16%) | 24 (17%) |
| Body mass index | |||
| <25 kg/m2 | 87 (25%) | 52 (25%) | 35 (25%) |
| 25–30 kg/m2 | 138 (39%) | 83 (39%) | 55 (39%) |
| ≥30 kg/m2 | 127 (36%) | 76 (36%) | 51 (36%) |
| HCV treatment history | |||
| Naïve | 198 (56%) | 113 (54%) | 85 (60%) |
| Relapse/breakthrough | 41 (12%) | 27 (13%) | 14 (10%) |
| Partial responder | 25 (7%) | 18 (9%) | 7 (5%) |
| Null responder | 38 (11%) | 27 (13%) | 11 (8%) |
| Treatment experienced, response unknown | 50 (14%) | 26 (12%) | 24 (17%) |
| Fibrosis stage+ | |||
| F0 | 7 (6%) | 6 (8%) | 1 (2%) |
| F1–F2 | 60 (48%) | 29 (38%) | 31 (62%) |
| F3 | 45 (36%) | 30 (39%) | 15 (30%) |
| F4 | 14 (11%) | 11 (14%) | 3 (6%) |
| Cirrhosis* | 73 (21%) | 48 (23%) | 25 (18%) |
| HCV subtype | |||
| 1a | 218 (62%) | 132 (63%) | 86 (61%) |
| 1b | 111 (32%) | 67 (32%) | 44 (31%) |
| 1 other/unknown | 23 (7%) | 12 (6%) | 11 (8%) |
| HCV viral load | |||
| <400,000 IU/mL | 92 (26%) | 57 (27%) | 35 (25%) |
| 400,000–799,999 IU/mL | 60 (17%) | 36 (17%) | 24 (17%) |
| ≥800,000 IU/mL | 189 (54%) | 114 (54%) | 75 (53%) |
| Missing | 11 (3%) | 4 (2%) | 7 (5%) |
| Platelet count (×109/L) | |||
| <150 | 110 (31%) | 68 (32%) | 42 (30%) |
| ≥150 | 229 (65%) | 139 (66%) | 90 (64%) |
| Missing | 13 (4%) | 4 (2%) | 9 (6%) |
HCV= hepatitis C virus;
+
Fibrosis measured using the Batts-Ludwig scale among subjects with liver biopsy performed (total=126, telaprevir=76, boceprevir=50);
*
Cirrhosis by clinical diagnosis or liver biopsy